| Nidal Jibawi, DO | |
|
12750 St Francis Dr, Crown Point, IN 46307-0264 | |
| (219) 757-6121 | |
| (219) 681-6897 |
| Full Name | Nidal Jibawi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 12750 St Francis Dr, Crown Point, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285138297 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 02006966A (Indiana) | Secondary |
| 207R00000X | Internal Medicine | 036.161980 (Illinois) | Secondary |
| 208M00000X | Hospitalist | 02006966A (Indiana) | Primary |
| Entity Name | Chest Physician Consultants, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760576359 PECOS PAC ID: 9931173937 Enrollment ID: O20040825000279 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
The Dow Chemical Company today announced Omega-9 Oils as its first Breakthrough to World Challenges, addressing one of the Company's 2015 Sustainability Goals in the area of health.
According to scientific research in the U.S. eating chocolate, especially dark chocolate, during pregnancy is good for mother and baby.
› Verified 3 days ago
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
The Dow Chemical Company today announced Omega-9 Oils as its first Breakthrough to World Challenges, addressing one of the Company's 2015 Sustainability Goals in the area of health.
According to scientific research in the U.S. eating chocolate, especially dark chocolate, during pregnancy is good for mother and baby.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nidal Jibawi, DO Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Nidal Jibawi, DO 12750 St Francis Dr, Crown Point, IN 46307-0264 Ph: (219) 757-6121 |
News Archive
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
The Dow Chemical Company today announced Omega-9 Oils as its first Breakthrough to World Challenges, addressing one of the Company's 2015 Sustainability Goals in the area of health.
According to scientific research in the U.S. eating chocolate, especially dark chocolate, during pregnancy is good for mother and baby.
› Verified 3 days ago
Nicole M Cataldi, D.O. Hospitalist Medicare: Medicare Enrolled Practice Location: 800 W Burrell Dr, Crown Point, IN 46307 Phone: 219-663-9913 Fax: 219-663-9923 | |
Dr. Yu Liu, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12750 St Francis Dr, Crown Point, IN 46307 Phone: 219-757-6121 Fax: 219-681-6897 | |
Usman Syed Ather, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 12750 St Francis Dr, Crown Point, IN 46307 Phone: 219-757-6121 Fax: 219-681-6897 | |
Kenneth Polezoes, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7310 W Lincoln Hwy, Crown Point, IN 46307 Phone: 219-322-4637 Fax: 219-322-5298 | |
Rayon Golding, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12750 St Francis Dr, Crown Point, IN 46307 Phone: 219-757-6121 Fax: 219-681-6897 | |
Zhipeng Zhang, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12750 St Francis Dr, Crown Point, IN 46307 Phone: 219-757-6121 Fax: 219-681-6897 | |
Jennifer Lynn Kelly, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1201 S Main St, Crown Point, IN 46307 Phone: 219-738-2100 Fax: 219-933-2288 |